Inhaled cancer drug tested in smokers – early study halted

NCT ID NCT06897735

Terminated Knowledge-focused Sponsor: Petrov, Andrey Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested whether inhaling the cancer drug afatinib works as well as taking it by mouth. Four healthy adult smokers received both forms in separate sessions to compare drug levels in the blood and lungs. The study was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Afatinib dimaleate (inhaled and oral forms)
What this could lead to: If successful, this could point toward a less toxic way to deliver afatinib directly to the lungs for treating lung cancer.
What could go wrong: This was a very early, small pilot study (only 4 participants) that was terminated, so results are limited. Inhaled delivery may not work as well as hoped, and side effects are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lip and oral cavity carcinoma lung cancer lung neoplasm melanoma Mouth Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER MELANOMA ORAL CANCER

Contacts and locations

Show contact details

Locations

Central Contact

Auckland, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.